21st August 2009

NovaBiotics selected to present data at high profile, international events

NovaBiotics announces that it has been selected to present the science behind its lead clinical product, Novexatin® and the platform from which it was derived through two poster presentations at ICAAC (Interscience Conference on Antimicrobial Agents and Chemotherapy - San Francisco, September 2009). The Company’s progress in peptide drug design and future scientific ambitions will be further communicated through an oral presentation at Engineering Protein & Peptide Therapeutics (San Diego, January 2010).  A talk at Bio-Europe (Vienna, November 2009) will facilitate an update for key opinion leaders and potential commercial partners on the Company’s commercial plans and future strategy.  NovaBiotics looks forward to meeting its existing and also new contacts and partners at these leading, international meetings.